Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: cherry grove who wrote (2950)	11/22/1997 8:55:00 AM
From: m33806	Respond to of 6136

With no change in the basic fundementals, at $39 and small change, this a rare chance to load up on the shares or some longer term calls. The May 50 gives one the chance of 5 times the money if we hit $70 by May exp. It gets one past two earnings releases and European approval. We have been offered a gift with this sell off.

To: cherry grove who wrote (2950)	11/22/1997 11:32:00 AM
From: PAL	Respond to of 6136

Cherry: most of the calls were sold by the big boys. The small investors think that buy buying calls on AGPH they can profit with small investment. Little that they know, most options expire worthless. The drop to 39 last Friday for Agouron occured at the later trading day. Thus all Nov call options 40 and above became worthless. Nobody ever admits that there is a deliberate trading to take the price of the stock near or below strike price. Nevertheless the actions make it suspect. Since AGPH is traded on NASDAQ, the Marker Makers control the price. As one wise man said: when you are in a watermelon yard, do not fix your shoelaces, and when you are in a apple farm, do not adjust your hat . Now that Nov option is gone, look for a bounce on Monday for Agouron. Then a year-end rally in December, especially with a boost from November data. Best to you Cherry. You are an inspiration of courage and strength. PAL